Frontline and Sequential Strategies in HER2-Positive Breast Cancer: Integrating Emerging Evidence into Practice

Segment 1 establishes the current treatment landscape for HER2-positive metastatic breast cancer (mBC) and highlights key unmet clinical needs.

Experts discuss evolving strategies and unmet needs in HER2-positive breast cancer treatment, focusing on emerging therapies and clinical trial insights.

Experts discuss the evolving strategies in HER2-positive breast cancer treatment, focusing on maintenance therapies and patient-specific approaches.

New trials reveal T-DXd's effectiveness in high-risk HER2-positive breast cancer, showing significant improvements in treatment response rates.

Experts unpack second-line HER2+ breast cancer choices, why T-DXd leads, and when T-DM1 or tucatinib matters—especially with brain mets.

Experts weigh how early HER2 escalation with T‑DXd reshapes metastatic sequencing, with tucatinib options and APHINITY’s long-term signals.

Experts weigh HER2+ metastatic options after T‑DXd, balancing tucatinib CNS benefit, ADC‑after‑ADC evidence, and patient toxicity or comorbidities.

Infusion bottlenecks, prior authorizations and travel barriers limit access to new HER2 therapies; upcoming trials test better sequencing and equity.

Clinicians show how to tailor HER2 treatment beyond guidelines, using proactive education and monitoring to curb ADC/TKI toxicities.

This segment emphasizes that multidisciplinary collaboration and survivorship planning are essential to safely deliver HER2-targeted therapies and support long-term patient outcomes.

This segment emphasizes the need to ensure equitable access to novel HER2-targeted therapies through financial and logistical support, accurate biomarker testing, and effective knowledge dissemination to community clinicians.